RESUMO
From September 28 to October 1, 2022, in New York City, the Sixth International Cancer Immunotherapy Conference was hosted jointly by the Cancer Research Institute (CRI), the American Association for Cancer Research, and the European Network for Cancer Immunotherapy. The four-day event covered the latest advances in cancer immunology and immunotherapy.
Assuntos
Neoplasias , Humanos , Neoplasias/terapia , ImunoterapiaRESUMO
From September 25 to 28, 2019, in Paris, France, the Fifth International Cancer Immunotherapy Conference was hosted jointly by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research. This year, roughly 1,300 people attended the 4-day event, which covered the latest advances in cancer immunology and immunotherapy.
Assuntos
Antineoplásicos Imunológicos/uso terapêutico , Fatores Imunológicos/uso terapêutico , Imunoterapia/métodos , Neoplasias/mortalidade , Pesquisa Translacional Biomédica/normas , Microambiente Tumoral/imunologia , Congressos como Assunto , Humanos , Neoplasias/imunologia , Neoplasias/terapia , Taxa de SobrevidaRESUMO
On September 30 to October 3, 2018, in New York City, the Fourth International Cancer Immunotherapy Conference (CICON) was hosted jointly by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology, and the American Association for Cancer Research (AACR). For the fourth straight year, more than 1,400 people attended the 4-day event, which covered the latest advances in cancer immunology and immunotherapy. This year's meeting also coincided with the announcement that the 2018 Nobel Prize in Medicine or Physiology would be awarded to one of CICON's attendees, James P. Allison.
Assuntos
Imunoterapia , Neoplasias/terapia , Animais , Humanos , Pesquisa Translacional BiomédicaRESUMO
On September 6 to 9, 2017, in Mainz, Germany, the Third International Cancer Immunotherapy Conference was hosted jointly by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research. For the third straight year, more than 1,400 people attended the four-day event, which covered the latest advances in cancer immunology and immunotherapy. This report provides an overview of the main topics discussed. Cancer Immunol Res; 6(1); 10-13. ©2017 AACR.
Assuntos
Imunoterapia , Neoplasias/imunologia , Neoplasias/terapia , Pesquisa Translacional Biomédica , Animais , Antígenos de Neoplasias/imunologia , Biomarcadores , Terapia Combinada , Terapia Genética , Humanos , Imunoterapia/efeitos adversos , Imunoterapia/métodos , Terapia de Alvo Molecular , Neoplasias/mortalidade , Neoplasias/patologia , Prognóstico , Resultado do TratamentoRESUMO
Immunotherapy is rapidly becoming a standard of care for many cancers. However, colorectal cancer had been generally resistant to immunotherapy, despite features in common with sensitive tumors. Observations of substantial clinical activity for checkpoint blockade in colorectal cancers with defective mismatch repair (microsatellite instability-high tumors) have reignited interest in the search for immunotherapies that could be extended to the larger microsatellite stable (MSS) population. The Cancer Research Institute and Fight Colorectal Cancer convened a group of scientists, clinicians, advocates, and industry experts in colorectal cancer and immunotherapy to compile ongoing research efforts, identify gaps in translational and clinical research, and provide a blueprint to advance immunotherapy. We identified lack of a T-cell inflamed phenotype (due to inadequate T-cell infiltration, inadequate T-cell activation, or T-cell suppression) as a broad potential explanation for failure of checkpoint blockade in MSS. The specific cellular and molecular underpinnings for these various mechanisms are unclear. Whether biomarkers with prognostic value, such as the immunoscores and IFN signatures, would also predict benefit for immunotherapies in MSS colon cancer is unknown, but if so, these and other biomarkers for measuring the potential for an immune response in patients with colorectal cancer will need to be incorporated into clinical guidelines. We have proposed a framework for research to identify immunologic factors that may be modulated to improve immunotherapy for colorectal cancer patients, with the goal that the biomarkers and treatment strategies identified will become part of the routine management of colorectal cancer. Cancer Immunol Res; 5(11); 942-9. ©2017 AACR.
Assuntos
Neoplasias Colorretais/terapia , Imunoterapia , Animais , Neoplasias Colorretais/imunologia , HumanosRESUMO
On September 25-28, 2016, in New York City, the Second International Cancer Immunotherapy Conference was cohosted by the Cancer Research Institute, the American Association for Cancer Research, the Association for Cancer Immunotherapy, and the European Academy of Tumor Immunology. This exciting conference brought together more than 1,400 participants, including scientists, clinicians, investors, and regulators, to discuss the latest scientific advances within the field of cancer immunotherapy. This conference report reviews the chief themes that emerged during the 4-day meeting. Cancer Immunol Res; 4(12); 996-1000. ©2016 AACR.
